  SMITHKLINE <SKB> AIMS FOR 10 PCT EARNINGS RAISE      PHILADELPHIA, March 16 - SmithKlin Beckman Corp pursu three-point stragei achiev 10 pct annual increas oper earn throughout remaind decade. 
    In 1986, SmithKlin earn 521.1 mln dlr 6.78 dlr per share revenu 3.6 billion dlrs. 
    The compani annual report nonpharmaceut busi plai major role meet earn growth target, fact grow faster pharmaceut business. 
    SmithKline, whose major product antiulc medic Tagamet, report intend improv earn exist products, expand product portfolio optim financi resources. 
    To bolster posit antiulc market, Tagamet met stiff competition, SmithKlin strategi develop over-the-count version Tagamet bolster two joint ventures, on <Wellcom PLC>, on pend ventur Japan. 
    SmithKlin Allergan Inc ey skin care product divis on billion dlr organ next five year grow more seven 10 pct annually. 
    Nondilut acquisit real possibility, Gavin Herbert, presid ey skin care product group report. 
In 1986, Allergan worldwid sale 433 mln dlrs. 
    It Smith Kline French Laboratori pharmaceut unit, 1986 sale 1.9 billion dlrs, file Food Drug Administr market approv number cardiovascular agents, includ tissu plasminogen activator, over next two years. 
    It SK Fs U.S. 
sale forc 20 pct larger 1987, more 1,000 sale personnel. 
    Smith Kline small clinic laboratori test unit, 1986 sale 373 mln dlrs, perform 24 mln test year, see increas employe drug test well test AIDS antibody. 
    Smith Kline depend share price cost money, bui back more shares. 
In last three years, bought back 25 pct shares. 
    SmithKlin begin year new manag team, includ new chief oper offic Georg Ebright.
